George, D. J., Halabi, S., Fleming, M. T., Heath, E. I., Tutrone, R., Sutton, L., … Armstrong, A. J. (2024). Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

George, Daniel J., Susan Halabi, Mark T. Fleming, Elisabeth I. Heath, Ronald Tutrone, Linda Sutton, Young E. Whang, et al. “Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

George DJ, Halabi S, Fleming MT, Heath EI, Tutrone R, Sutton L, et al. Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

George, Daniel J., et al. “Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

George DJ, Halabi S, Fleming MT, Heath EI, Tutrone R, Sutton L, Whang YE, Lewis BE, Humeniuk MS, Harrison MR, Kephart J, Hurrelbrink J, Rasmussen J, Shobe K, Anand M, Reyes-Martinez M, Howard L, Patierno SR, Freedman JA, Armstrong AJ. Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2024.